Skip to main content
Terug
Watch Compare

Autolus Therapeutics plc

Datakwaliteit: 100%
AUTL
Nasdaq Manufacturing Chemicals
€ 1,48
▼ € 0,01 (-0,67%)
Marktkapitalisatie: 393,89 M
Prijs
€ 1,48
Marktkapitalisatie
393,89 M
Dagbereik
€ 1,45 — € 1,54
52-Weeksbereik
€ 1,11 — € 2,70
Volume
1.822.728
Openen € 1,49
50D / 200D Gem.
€ 1,48
0,11% above
50D / 200D Gem.
€ 1,69
12,43% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -302,61 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)644,94%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-93,98%
Onder sectorgemiddelde (-53,47%)
ROIC-34,70%
Net Margin-381,40%
Op. Margin-358,87%

Veiligheid

Debt / Equity
N/A
Current Ratio6,19
Interest Coverage-7,38

Waardering

PE (TTM)
-1,37
Boven sectorgemiddelde (-1,47)
P/B Ratio1,48
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,4 -1,5
P/B 1,5 1,6
ROE % -94,0 -53,5
Net Margin % -381,4 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0,90% weight
CANC logo CANC Tema Oncology ETF
0,31% weight
SHISX SHISX
0,02% weight
SHSAX SHSAX
0,02% weight
SHSCX SHSCX
0,02% weight
NARCX NARCX
0,01% weight
NAPIX NAPIX
0,01% weight
ISCWX ISCWX
0,01% weight
VVJFX VVJFX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 644,94% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 75,39 M Net Income (TTM) -287,53 M
ROE -93,98% ROA -41,58%
Gross Margin N/A Operating Margin -358,87%
Net Margin -381,40% Free Cash Flow (TTM) -302,61 M
ROIC -34,70% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6,19
Interest Coverage -7,38 Asset Turnover 0,11
Working Capital 431,51 M Tangible Book Value 245,17 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,37 Forward P/E N/A
P/B Ratio 1,48 P/S Ratio 5,22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -76,83%
Market Cap 393,89 M Enterprise Value 307,77 M
Per Share
EPS (Diluted TTM) -1,08 Revenue / Share 0,28
FCF / Share -1,14 OCF / Share -1,07
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 25,26% FCF Conversion 105,25%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 75,39 M 10,12 M — — —
Net Income -287,53 M -220,66 M -208,38 M -148,84 M -142,10 M
EPS (Diluted) -1,08 -0,86 -1,20 -1,57 -1,97
Gross Profit — — — — —
Operating Income -270,54 M -241,43 M -179,70 M -168,05 M -165,00 M
EBITDA — — — — —
R&D Expenses 117,69 M 138,44 M 130,48 M 141,99 M 134,79 M
SG&A Expenses 131,87 M 101,09 M — — —
D&A 8,30 M 7,55 M 6,57 M 7,42 M 8,46 M
Interest Expense 36,67 M 9,29 M 45,07 M 8,91 M 1,11 M
Income Tax 1,97 M 1,53 M -19.500,0 -24,37 M -23,89 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 589,07 M 782,73 M 375,38 M 490,27 M 405,56 M
Total Liabilities 410,94 M 355,40 M 263,91 M 191,60 M 92,24 M
Shareholders' Equity 178,13 M 427,33 M 111,47 M 298,67 M 313,32 M
Total Debt — — — — —
Cash & Equivalents 104,13 M 227,38 M 239,57 M 382,44 M —
Current Assets 435,92 M 660,93 M 275,30 M 425,77 M 346,95 M
Current Liabilities 73,44 M 60,74 M 44,74 M 46,37 M 28,55 M